Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (AMRN) and Mirum Pharmaceuticals (MIRM).
Amarin (AMRN)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin, with a price target of $6.00. The company’s shares closed last Thursday at $5.37.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.8% and a 46.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $10.50.
See today’s analyst top recommended stocks >>
Mirum Pharmaceuticals (MIRM)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Mirum Pharmaceuticals today and set a price target of $52.00. The company’s shares closed last Thursday at $19.38.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 16.3% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Paratek Pharmaceuticals, and Aurinia Pharmaceuticals.
Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $41.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
